FDA seeks genome-based drug data.

@article{Hampton2004FDASG,
  title={FDA seeks genome-based drug data.},
  author={Tracy A Hampton},
  journal={JAMA},
  year={2004},
  volume={291 1},
  pages={
          32-3
        }
}
View on PubMed
doi.org
4 Citations
Highly Influential Citations
1
Background Citations
2

4 Citations

Citation Type

Citation Type

A critical analysis of barriers to the clinical implementation of pharmacogenomics
TLDR
A framework for successful clinical uptake of pharmacogenomics is emerging, which utilises genetic information to guide the selection of new drugs most likely to survive increasingly demanding safety and efficacy assessments.
Regulatory Perspectives on Pharmacogenomics: A Review of the Literature on Key Issues Faced by the United States Food and Drug Administration
TLDR
This review identifies issues faced by the FDA with respect to PGx, which the FDA is addressing through several initiatives and illustrates the complex issues involved in developing, implementing, and adopting new technologies.
A lay prescription for tailor-made drugs--focus group reflections on pharmacogenomics.
The Promise of Pharmacogenomics
TLDR
The assumption that mass-produced medical treatment is satisfactory or worse, that it is the best that the authors can achieve may prevent humanity from venturing anywhere near its physiological potential.